At a Glance
- Company: Johnson & Johnson
- Location: New Jersey, US
- Focus area: Drug discovery, manufacturing and regulatory work
- Key claim: Lead optimisation time cut by 50%
- Next steps: Broader AI deployment across core workflows
What happened?
Johnson & Johnson said it is using artificial intelligence to halve the time it takes to generate and optimise new drug development leads, according to its chief information officer Jim Swanson. The company also said AI has reduced the time needed to prepare clinical trial reports from 700-900 hours to about 15 minutes.
Why does it matter?
The comments show how big pharma is starting to capture practical productivity gains from AI, even if the technology is not yet inventing new medicines end to end. Cutting lead-generation and regulatory-document time can speed up development, lower costs and free scientists to focus on higher-value decisions.
Who’s behind it?
Johnson & Johnson is one of the world’s largest healthcare companies, with businesses spanning pharmaceuticals and medical devices. Swanson said J&J is concentrating on a narrower set of high-impact use cases, including drug development, supply-chain optimisation and AI-enabled products.
How was it achieved?
J&J is using AI to screen a broader “potential universe” of chemical compounds and biologics, then narrow those candidates more quickly. It is also applying AI to regulatory documentation, where language models can help turn trial data into submission-ready drafts much faster than manual workflows.
What’s next?
Swanson said truly discovering and launching new products entirely through AI is still “a ways away”, but J&J expects continued efficiency gains as it expands adoption. The company’s experience fits a wider industry trend in which AI is already helping with trial design, patient screening and regulatory writing before it fully transforms molecule discovery.